Maxigen Biotech Inc. (TPE:1783)

Market Cap	3.65B -10.6%
Revenue (ttm)	811.56M +19.2%
Net Income	265.31M +39.5%
EPS	2.94 +38.7%
Shares Out	89.68M
PE Ratio	13.86
Forward PE	n/a
Dividend	0.83 (1.99%)
Ex-Dividend Date	Sep 5, 2025

Volume	1,000
Average Volume	79,864
Open	41.80
Previous Close	41.75
Day's Range	40.70 - 41.80
52-Week Range	40.75 - 48.85
Beta	0.31
RSI	32.75
Earnings Date	Mar 20, 2026

About Maxigen Biotech

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, electronic instructions for use, and medical aesthetics, as well as engages in collagen purification activities. It also ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1783

Financial Performance

In 2025, Maxigen Biotech's revenue was 811.56 million, an increase of 19.23% compared to the previous year's 680.65 million. Earnings were 265.31 million, an increase of 39.52%.